谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Camrelizumab Plus Rivoceranib Vs Sorafenib As First-Line Therapy for Unresectable Hepatocellular Carcinoma (uhcc): Final Overall Survival Analysis of the Phase 3 CARES-310 Study.

Arndt Vogel,Stephen Lam Chan,Zhenggang Ren,Yuxian Bai,Shanzhi Gu,Xiaoyan Lin,Zhendong Chen,Weidong Jia,Yongdong Jin,Yabing Guo,Xiaohua Hu,Alexander Valerievich Sultanbaev,Monika Pazgan-Simon, Margaryta Pisetska, Tsz Keung Nip, Haisong Zhang, Jinghua Du,Ann-Lii Cheng,Ahmed Omar Kaseb,Shukui Qin

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用 0|浏览2
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要